127 related articles for article (PubMed ID: 235636)
1. The effect of liver disease in man on the disposition of phenobarbital.
Alvin J; McHorse T; Hoyumpa A; Bush MT; Schenker S
J Pharmacol Exp Ther; 1975 Jan; 192(1):224-35. PubMed ID: 235636
[TBL] [Abstract][Full Text] [Related]
2. Metabolic fate of phenobarbital. A quantitative study of p-hydroxyphenobarbital elimination in man.
Whyte MP; Dekaban AS
Drug Metab Dispos; 1977; 5(1):63-70. PubMed ID: 13977
[TBL] [Abstract][Full Text] [Related]
3. The effects of age and liver disease on the disposition and elimination of diazepam in adult man.
Klotz U; Avant GR; Hoyumpa A; Schenker S; Wilkinson GR
J Clin Invest; 1975 Feb; 55(2):347-59. PubMed ID: 1127104
[TBL] [Abstract][Full Text] [Related]
4. Impaired elimination of meperidine in patients with liver disease.
McHorse TS; Klotz U; Wilkinson G; Schenker S
Trans Assoc Am Physicians; 1974; 87():281-7. PubMed ID: 4456737
[No Abstract] [Full Text] [Related]
5. Altered hepatobiliary disposition of acetaminophen metabolites after phenobarbital pretreatment and renal ligation: evidence for impaired biliary excretion and a diffusional barrier.
Brouwer KL; Jones JA
J Pharmacol Exp Ther; 1990 Feb; 252(2):657-64. PubMed ID: 2313593
[TBL] [Abstract][Full Text] [Related]
6. Clinical findings in patients with hepatitis and abnormal bile duct epithelium.
Christoffersen P; Poulsen H; Winkler K
Scand J Gastroenterol; 1970; 5(2):117-21. PubMed ID: 5429872
[No Abstract] [Full Text] [Related]
7. Urinary sodium balance in patients with cirrhosis: relationship to quantitative parameters of liver function.
Wensing G; Lotterer E; Link I; Hahn EG; Fleig WE
Hepatology; 1997 Nov; 26(5):1149-55. PubMed ID: 9362355
[TBL] [Abstract][Full Text] [Related]
8. The effects of acute infectious hepatitis and cirrhosis of the liver on the nonerythropoietic component of early bilirubin.
Tarao K; Fukushima K; Endo O; Kamiyo A
J Lab Clin Med; 1976 Feb; 87(2):240-50. PubMed ID: 1245790
[TBL] [Abstract][Full Text] [Related]
9. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
[TBL] [Abstract][Full Text] [Related]
10. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
11. [Changes in renal function in patients with severe hepatitis and liver cancer with cirrhosis during orthotopic liver transplantation].
Li XY; Hei ZQ; Li SR; Shen N
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2007 Jul; 19(7):386-9. PubMed ID: 17631701
[TBL] [Abstract][Full Text] [Related]
12. Impaired biliary excretion of acetaminophen glucuronide in the isolated perfused rat liver after acute phenobarbital treatment and in vivo phenobarbital pretreatment.
Studenberg SD; Brouwer KL
J Pharmacol Exp Ther; 1992 Jun; 261(3):1022-7. PubMed ID: 1602370
[TBL] [Abstract][Full Text] [Related]
13. Disposition of bupropion in healthy volunteers and subjects with alcoholic liver disease.
DeVane CL; Laizure SC; Stewart JT; Kolts BE; Ryerson EG; Miller RL; Lai AA
J Clin Psychopharmacol; 1990 Oct; 10(5):328-32. PubMed ID: 2124217
[TBL] [Abstract][Full Text] [Related]
14. Urinary kallikrein excretion in chronic liver disease and effect of indomethacin.
Kawasaki H; Murawaki Y; Hirayama C
Am J Gastroenterol; 1986 Jan; 81(1):67-70. PubMed ID: 3510529
[TBL] [Abstract][Full Text] [Related]
15. Hepatocellular carcinoma and liver cirrhosis: assessment of the liver function after Yttrium-90 radioembolization with resin microspheres or after CT-guided high-dose-rate brachytherapy.
Rühl R; Seidensticker M; Peters N; Mohnike K; Bornschein J; Schütte K; Amthauer H; Malfertheiner P; Pech M; Ricke J
Dig Dis; 2009; 27(2):189-99. PubMed ID: 19546558
[TBL] [Abstract][Full Text] [Related]
16. Dipyrone metabolism in liver disease.
Zylber-Katz E; Caraco Y; Granit L; Levy M
Clin Pharmacol Ther; 1995 Aug; 58(2):198-209. PubMed ID: 7648770
[TBL] [Abstract][Full Text] [Related]
17. The effect of cirrhosis on the disposition and elimination of clindamycin.
Avant GR; Schenker S; Alford RH
Am J Dig Dis; 1975 Mar; 20(3):223-30. PubMed ID: 1168411
[TBL] [Abstract][Full Text] [Related]
18. Half-life time or clearance of indocyanine green in patients with liver disease.
Gilmore IT; Marigold JH; Thompson RP
Hepatogastroenterology; 1982 Apr; 29(2):55-7. PubMed ID: 7084884
[TBL] [Abstract][Full Text] [Related]
19. Corticosteroid-induced changes in urea metabolism in patients with hepatocellular disease.
Jones EA; Cain GD; Dickinson G
Gastroenterology; 1972 Apr; 62(4):612-7. PubMed ID: 5020873
[No Abstract] [Full Text] [Related]
20. [Hepatic clearance of 99mTc-p-butyl HIDA in liver diseases. Correlations with routine hematochemical parameters of liver function].
Custro N; De Francisci MC; Patanella I; Scafidi V; Indovina I
Minerva Med; 1984 Nov; 75(42):2527-32. PubMed ID: 6083507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
